Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5824255 | 0.92 | GABRA1 (0.36) | SRCKDM4EGPR84ALDH1A1GABRA1 | |
| SCHEMBL2143338 | 0.90 | SRC (0.39) | SRCKDM4EGPR84ALDH1A1ANPEP | |
| SCHEMBL2732358 | 0.89 | KDM4E (0.43) | SRCKDM4EGPR84ALDH1A1 | |
| SCHEMBL407519 | 0.83 | INPPL1 (0.47) | SRCKDM4EALDH1A1GABRA1GABRB2 | |
| SCHEMBL29044426 | 0.82 | INPPL1 (0.46) | SRCKDM4EALDH1A1GABRA1GABRB2 | |
| SCHEMBL16779898 | 0.82 | GABRA1 (0.36) | SRCKDM4EALDH1A1GABRA1GABRB2 | |
| SCHEMBL3474948 | 0.81 | KDM4E (0.45) | KDM4EALDH1A1 | |
| Phosphoric Acid SCHEMBL3968523 | 0.80 | GABRA1 (0.43) | KDM4EALDH1A1GABRA1GABRB2MEN1 | |
| SCHEMBL407518 | 0.80 | GABRA1 (0.40) | KDM4EALDH1A1GABRA1GABRB2MEN1 | |
| SCHEMBL278393 | 0.78 | HRH1 (0.46) | KDM4EALDH1A1GABRA1GABRB2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4683726-B2 | — | — | 2011-05-18 | — | — | JP | claimed |
| JP-2002526571-A | — | — | 2002-08-20 | — | — | JP | claimed |
| EP-1115728-A1 | TRIARYL PHOSPHATE ESTER COMPOSITION | Akzo Nobel N.V. (NL) | 2001-07-18 | — | — | EP | claimed |
| US-6242631-B1 | Triaryl phosphate ester composition | AKZO NOBEL NV (NL) | 2001-06-05 | — | — | US | claimed |
| WO-2000017210-A1 | TRIARYL PHOSPHATE ESTER COMPOSITION | AKZO NOBEL N.V. (NL) | 2000-03-30 | — | — | WO | claimed |
| EP-0573082-B1 | Triaryl phosphate ester composition and process for its preparation | FMC CORP (US) | 1998-01-14 | — | — | EP | claimed |
| EP-0573082-A2 | Triaryl phosphate ester composition and process for its preparation | FMC CORPORATION (US) | 1993-12-08 | — | — | EP | claimed |
| US-5206404-A | Purifying by passing through thin film evaporators; oxidation, wear, heat, hydroytic stability | FMC CORPORATION (US) | 1993-04-27 | — | — | US | claimed |
| JP-6009661-A | — | — | None | — | — | JP | disclosed |
| CN-110337484-B | Antimony-free flame-retardant epoxy resin composition | 溴化合物有限公司 | 2022-05-24 | — | — | CN | disclosed |
| EP-3006543-B1 | POLYFUNCTIONAL LUBRICANT COMPOSITION | ADEKA CORP (JP) | 2021-05-26 | — | — | EP | disclosed |
| EP-2446005-B1 | ANTI-WEAR AGENTS WITH A REDUCED NEUROTOXICITY | NYCO (FR) | 2015-04-29 | — | — | EP | disclosed |
| EP-2446005-A1 | ANTI-WEAR AGENTS WITH A REDUCED NEUROTOXICITY | Nyco SA (FR) | 2012-05-02 | — | — | EP | disclosed |
| US-20120101015-A1 | ANTI-WEAR AGENTS WITH A REDUCED NEUROTOXICITY | NYCO SA (FR) | 2012-04-26 | — | — | US | disclosed |
| EP-0573082-B1 | Triaryl phosphate ester composition and process for its preparation | FMC CORP (US) | 1998-01-14 | — | — | EP | disclosed |
| JP-H069661-A | TRIALKYLPHOSPHATE ESTER COMPOSITION AND ITS PRODUCTION | FMC CORP | 1994-01-18 | — | — | JP | disclosed |
| EP-0573082-A2 | Triaryl phosphate ester composition and process for its preparation | FMC CORPORATION (US) | 1993-12-08 | — | — | EP | disclosed |
| EP-0573082-A2 | Triaryl phosphate ester composition and process for its preparation | FMC CORPORATION (US) | 1993-12-08 | — | — | EP | disclosed |
| US-5206404-A | Purifying by passing through thin film evaporators; oxidation, wear, heat, hydroytic stability | FMC CORPORATION (US) | 1993-04-27 | — | — | US | disclosed |
| US-5206404-A | Purifying by passing through thin film evaporators; oxidation, wear, heat, hydroytic stability | FMC CORPORATION (US) | 1993-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101015-A1 | ANTI-WEAR AGENTS WITH A REDUCED NEUROTOXICITY | SSB, PRNP, TARDBP | SRC 1974/4885KDM4E 4197/4885GPR84 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.